Are We Seeing Eye to Eye?
Interested in a partnership to in-license our clinical drug candidates?
Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances
For more details, click here for the full news release.
APX2009 Intravitreal Formulation
APX2009 is a second-generation preclinical product candidate analog of APX3330. In mouse models of retinal neovascularization, APX2009 was effective in decreasing lesion size as well as improved efficacy against the Ref-1 target compared to APX3330. An intravitreal formulation could present itself as an alternative to APX3330’s oral formulation (as published in the Journal of Pharmacology and Experimental Therapeutics).
| Product Candidate | Indication | Development Stage | Anticipated Milestones | |||||
|---|---|---|---|---|---|---|---|---|
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Regulatory Approval | ||||
Partnering-Focused Development |
||||||||
| APX2009 Intravitreal | DME, Wet Age-Related Macular Degeneration (wAMD) |
Preclinical in progress
|
Phase 1 not started
|
Phase 2 not started
|
Phase 3 not started
|
Regulatory Approval not started
|
Seeking partner funding for IND enabling studies and further development |
|